Cargando…
EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer
Recent findings suggested a benefit of anti-EGFR therapy for basal-like muscle-invasive bladder cancer (MIBC). However, the impact on bladder cancer with substantial squamous differentiation (Sq-BLCA) and especially pure squamous cell carcinoma (SCC) remains unknown. Therefore, we comprehensively ch...
Autores principales: | Rose, Michael, Maurer, Angela, Wirtz, Julia, Bleilevens, Andreas, Waldmann, Tanja, Wenz, Maximilian, Eyll, Marie, Geelvink, Mirja, Gereitzig, Melanie, Rüchel, Nadine, Denecke, Bernd, Eltze, Elke, Herrmann, Edwin, Toma, Marieta, Horst, David, Grimm, Tobias, Denzinger, Stefan, Ecke, Thorsten, Vögeli, Thomas Alexander, Knuechel, Ruth, Maurer, Jochen, Gaisa, Nadine T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605436/ https://www.ncbi.nlm.nih.gov/pubmed/32978523 http://dx.doi.org/10.1038/s41388-020-01465-y |
Ejemplares similares
-
Diagnostic and Prognostic Implications of FGFR3(high)/Ki67(high) Papillary Bladder Cancers
por: Geelvink, Mirja, et al.
Publicado: (2018) -
Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer
por: Wucherpfennig, Sophie, et al.
Publicado: (2021) -
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
por: Morsch, Ronja, et al.
Publicado: (2020) -
Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer: a putative therapeutic target for a small subgroup
por: Baldia, Philipp H., et al.
Publicado: (2016) -
Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer
por: Jung, Max, et al.
Publicado: (2023)